---
title: "Medicare will cover weight-loss drugs for the first time, from July 1"
description: "In a notable reversal of long-standing policy, Medicare will begin helping older Americans pay for the blockbuster weight-loss drugs known as GLP-1s, starting July 1 — opening access, for a price, to medicines that have been out of reach for many on the program."
category: "Business"
category_url: https://newsparlor.com/category/business
author: "Hannah Brooks"
published: 2026-06-30T09:00:00.000Z
updated: 2026-06-30T09:00:00.000Z
canonical: https://newsparlor.com/article/medicare-glp1-obesity-drug-coverage-bridge
tags: ["medicare", "glp-1", "obesity", "health-policy", "united-states"]
---
# Medicare will cover weight-loss drugs for the first time, from July 1

In a notable reversal of long-standing policy, Medicare will begin helping older Americans pay for the blockbuster weight-loss drugs known as GLP-1s, starting July 1 — opening access, for a price, to medicines that have been out of reach for many on the program.

For years, older Americans hoping that Medicare would help pay for the new generation of weight-loss drugs were told no — the program was, by law, barred from covering medicines used purely to shed pounds. That changes on July 1.

## A new bridge

Under a temporary initiative called the Medicare GLP-1 Bridge, eligible enrollees in Medicare's Part D drug benefit will be able to get certain GLP-1 medications for a flat copay of $50 a month, [NPR reported](https://www.npr.org/2026/05/06/nx-s1-5812662/medicare-bridge-glp1-drugs-copay). The program, which runs from July 1, 2026 through the end of 2027, covers three drugs approved for weight loss: Novo Nordisk's Wegovy, in pill and injectable forms; the KwikPen version of Eli Lilly's Zepbound; and a newer pill, Foundayo, [according to the Centers for Medicare & Medicaid Services](https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge).

## Who can get them

Not everyone with extra weight will qualify. Beneficiaries become eligible if they have a body mass index of 27 or higher together with a weight-related condition such as heart disease or prediabetes; those with a BMI of 35 or above qualify automatically, [CBS News reported](https://www.cbsnews.com/news/medicare-glp1-weight-loss-drug-coverage-july-1/). By one analysis, the program could reach as many as 14 million people, though the conditions narrow the field. There are catches: the $50 copay does not count toward a member's deductible or annual out-of-pocket limit, and low-income beneficiaries cannot apply the usual "Extra Help" subsidies to these prescriptions.

## Why it is a big deal

The significance lies in the price. At retail, GLP-1 drugs can run to roughly $1,000 or more a month — a sum well beyond the reach of many seniors on fixed incomes, and the reason Medicare's exclusion mattered so much. The medicines, developed for diabetes and now hugely popular for weight loss, have driven a global boom for their makers, Novo Nordisk (Wegovy and Ozempic) and Eli Lilly (Zepbound and Mounjaro), and reshaped how obesity is treated.

## Cost versus value

The change is not without controversy. Obesity is common among older Americans, and supporters argue that treating it could prevent costlier illness down the line. But covering expensive drugs for a large population could also impose significant costs on a program already under financial strain — the central tension in a debate that this pilot, in effect, begins to test. Officials have framed the Bridge as a stepping stone toward a fuller demonstration program expected in 2027, after which the question of whether to make such coverage permanent will likely return to Washington. For now, patients curious whether the drugs are right for them are, as ever, advised to talk to their doctors.